AbbVie Inc (ABBV)vsChampions Oncology Inc (CSBR)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
CSBR
Champions Oncology Inc
$5.10
+0.09%
HEALTHCARE · Cap: $70.98M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 108248% more annual revenue ($64.39B vs $59.42M). ABBV leads profitability with a 9.8% profit margin vs -2.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
CSBR
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+42.5%
Fair Value
$10.26
Current Price
$5.10
$5.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 18.2x book value
Smaller company, higher risk/reward
Elevated debt levels
ROE of -53.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : CSBR
Revenue growth of 12.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : CSBR
The primary concerns for CSBR are Price/Book, Market Cap, Debt/Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while CSBR is a turnaround play — different risk/reward profiles.
CSBR carries more volatility with a beta of 0.40 — expect wider price swings.
CSBR is growing revenue faster at 12.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 25/100) and 10.2% revenue growth. CSBR offers better value entry with a 42.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Champions Oncology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Champions Oncology, Inc. develops and sells technology products and solutions to customize the development and use of cancer drugs in the United States. The company is headquartered in Hackensack, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?